Hong, Mi Jeong <br/><br/>
A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.  [electronic resource] 

 -  Oncotarget  Mar 2016 
 - 15948-58 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.7433  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Binding Sites<br/>Biomarkers, Tumor--analysis<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cisplatin--therapeutic use<br/>Female<br/>Gene Expression Regulation, Neoplastic--genetics<br/>Genotype<br/>Humans<br/>Kaplan-Meier Estimate<br/>Lung Neoplasms--drug therapy<br/>Male<br/>MicroRNAs--genetics<br/>Middle Aged<br/>Paclitaxel--therapeutic use<br/>Polymorphism, Single Nucleotide<br/>Proto-Oncogene Protein c-ets-2--genetics